NO20056196L - Makrocykliske kinazolinderivater som antiproliferative midler - Google Patents
Makrocykliske kinazolinderivater som antiproliferative midlerInfo
- Publication number
- NO20056196L NO20056196L NO20056196A NO20056196A NO20056196L NO 20056196 L NO20056196 L NO 20056196L NO 20056196 A NO20056196 A NO 20056196A NO 20056196 A NO20056196 A NO 20056196A NO 20056196 L NO20056196 L NO 20056196L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- represent
- 2alkyl
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- -1 2-pyrrolidinonyl Chemical group 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Sammendrag Den foreliggende oppfinnelse vedrører forbindelsene med formel N-oksidformene, de farmasøytisk akseptable addisjonssalter og de stereokjemisk isomere former derav, hvori Z representerer NH; Y representerer -C3-9 alkyl-, -C2-9 alkenyl-, -C3-7 alkyl-CO-NH eventuelt substituert med amino, mono - eller di(C1-4 alkyl)amino eller C1-4 alkyloksykarbonylamino-, -C3-7 alkenyl-CO-NH- eventuelt substituert med amino, mono- eller di(C1- 4 alkyl)amino- eller C1-4 alkyloksykarbonylamino-, C1-5alkyl-NR13-C1-5 alkyl-,-C1-5 alkyl-NR14-CO-C1-5 alkyl-,-C1-6 alkyl-CO-NH-, -C 1-5 alkyl-CO NR15-C 1-5 alkyl-, -C 1-3 alkyl-NH-CO-Het20-, -C1-2alkyl-CO-Het21-CO-,-C1-2alkyl-NH-CO-CR16R17-NH-, -C1-2alkyl-CO-NH-CR18R19-CO-,-C1-2 alkyl-CO-NR20-C1-3alkyl-CO-eller -NR22-CO-C1-3alkyl-NH-; X1 representerer en direkte binding, O eller -O-C1-2alkyl-; X2 representerer en direkte binding, -CO-C1-2alkyl-, NR12, -NR12-C 1-2alkyl-, -O-N=CH- eller-C1-2 alkyl-; R1 og R2 representerer hver uavhengig hydrogen eller halo; R3 representerer hydrogen; R4 representerer hydrogen eller C1-4 alkyloksy; R12 og R13 representerer hver uavhengig hydrogen eller C1-4 alkyl; R14 og R15 representerer hydrogen; R16 og R17 representerer hver uavhengig hydrogen eller C1-4 alkyl; R18 og R19 representerer hver uavhengig hydrogen eller C1-4 alkyl eventuelt substituert med fenyl eller hydroksy; R20 og R21 representerer hver uavhengig hydrogen eller C1-4 alkyl eventuelt substituert med C1-4 alkyloksy; Het20, Het21 og Het22 representerer hver uavhengig en heterocykel valgt fra gruppen bestående av pyrrolidinyl, 2-pyrrolidinonyl eller piperidinyl eventuelt substituert med hydroksy.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0305723 | 2003-05-27 | ||
| EP0310266 | 2003-09-15 | ||
| EP0351061 | 2003-12-18 | ||
| PCT/EP2004/005621 WO2004105765A1 (en) | 2003-05-27 | 2004-05-25 | Macrocyclic quinazoline derivatives as antiproliferative agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20056196L true NO20056196L (no) | 2005-12-28 |
| NO334209B1 NO334209B1 (no) | 2014-01-13 |
Family
ID=33493782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20056196A NO334209B1 (no) | 2003-05-27 | 2005-12-27 | Tyrosinkinaseinhibitorer for fremstilling av medikamenter i behandling av celleproliferasjonsrelaterte lidelser |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7648975B2 (no) |
| EP (2) | EP2305687A1 (no) |
| JP (1) | JP4887151B2 (no) |
| KR (1) | KR101143878B1 (no) |
| CN (1) | CN102718775B (no) |
| AR (2) | AR045687A1 (no) |
| AT (1) | ATE544454T1 (no) |
| AU (1) | AU2004243487B2 (no) |
| BR (1) | BRPI0410714B8 (no) |
| CA (1) | CA2525214C (no) |
| CL (1) | CL2004001267A1 (no) |
| CO (1) | CO5640038A2 (no) |
| CY (1) | CY1113002T1 (no) |
| DK (1) | DK1633365T3 (no) |
| EA (1) | EA009064B1 (no) |
| ES (1) | ES2381976T3 (no) |
| HR (1) | HRP20120351T1 (no) |
| IL (3) | IL172154A0 (no) |
| IS (1) | IS3030B (no) |
| JO (1) | JO2785B1 (no) |
| MX (1) | MXPA05012762A (no) |
| MY (1) | MY148633A (no) |
| NO (1) | NO334209B1 (no) |
| NZ (1) | NZ544154A (no) |
| PA (1) | PA8603801A1 (no) |
| PL (1) | PL1633365T3 (no) |
| PT (1) | PT1633365E (no) |
| SI (1) | SI1633365T1 (no) |
| TW (3) | TWI379835B (no) |
| UA (1) | UA84010C2 (no) |
| WO (1) | WO2004105765A1 (no) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO339891B1 (no) * | 2004-12-08 | 2017-02-13 | Janssen Pharmaceutica Nv | MTKI kinazolinderivater |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| US20050165031A1 (en) * | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Urea derivatives as ABL modulators |
| CA2549869C (en) | 2003-12-18 | 2015-05-05 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| CA2549728C (en) | 2003-12-18 | 2015-07-21 | Janssen Pharmaceutica N.V. | 3-cyano-quinoline derivatives with antiproliferative activity |
| MY169441A (en) | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| CN101163684B (zh) | 2005-02-23 | 2012-08-29 | 盐野义制药株式会社 | 具有酪氨酸激酶抑制作用的喹唑啉衍生物 |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| NZ564179A (en) * | 2005-06-30 | 2010-09-30 | Janssen Pharmaceutica Nv | Cyclic anilino - pyridinotriazines as GSK-3 inhibitors |
| MX2009000456A (es) | 2006-07-13 | 2009-01-27 | Janssen Pharmaceutica Nv | Derivados de quinazolina mtki. |
| JP2009242240A (ja) * | 2006-08-04 | 2009-10-22 | Mebiopharm Co Ltd | 含ホウ素キナゾリン誘導体 |
| WO2008033748A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| BRPI0715016A2 (pt) | 2006-09-11 | 2013-05-28 | Curis Inc | composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EA200970420A1 (ru) * | 2006-10-27 | 2009-12-30 | Янссен Фармацевтика Нв | Применение mtki 1 для лечения или предупреждения рака кости |
| EP2077843A1 (en) * | 2006-10-27 | 2009-07-15 | Janssen Pharmaceutica N.V. | Use of a mt kinase inhibitor for treating or preventing brain cancer |
| JP2010507626A (ja) * | 2006-10-27 | 2010-03-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｖｅｇｆｒ３阻害剤としての大環状キナゾリン誘導体 |
| CA2664114A1 (en) * | 2006-10-27 | 2008-05-02 | Janssen Pharmaceutica Nv | A method for profiling kinase inhibitors |
| WO2008087736A1 (ja) * | 2007-01-19 | 2008-07-24 | Ube Industries, Ltd. | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2009016132A1 (en) | 2007-07-27 | 2009-02-05 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法 |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| WO2013126015A1 (en) | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
| EP2822953B9 (en) * | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| JP6382997B2 (ja) * | 2014-02-07 | 2018-08-29 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC RIVER AND PHOSPHOLIPASE D AND PURIFICATION OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| EP3423113B1 (en) | 2016-02-29 | 2020-09-02 | Oncodesign S.A. | Radiolabeled macrocyclic egfr inhibitor |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| MX2020005927A (es) * | 2017-12-07 | 2020-10-07 | Amplyx Pharmaceuticals Inc | Agentes antifunales derivados de piridina heterociclica sustituida. |
| AU2019294474B2 (en) | 2018-06-25 | 2025-01-02 | Basilea Pharmaceutica International Ag, Allschwil | Pyridine derivatives substituted by heterocyclic ring and amino group |
| UY39061A (es) * | 2020-01-31 | 2022-01-31 | Oncodesign Sa | Inhibidores macrocíclicos de rip2-cinasa |
| WO2021216440A1 (en) * | 2020-04-20 | 2021-10-28 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
| AU2022413540A1 (en) | 2021-12-16 | 2024-07-18 | Kinnate Biopharma Inc. | Inhibitors of met kinase |
| WO2024017258A1 (zh) * | 2022-07-19 | 2024-01-25 | 百极弘烨(南通)医药科技有限公司 | Egfr小分子抑制剂、含其的药物组合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE558251A (no) * | 1956-06-11 | |||
| DE2423536A1 (de) * | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
| NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
| US4126688A (en) | 1976-05-17 | 1978-11-21 | Janssen Pharmaceutica N.V. | Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| BR9914162A (pt) | 1998-10-01 | 2001-06-26 | Astrazeneca Ab | Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo |
| FR2809400B1 (fr) * | 2000-05-25 | 2004-04-09 | Inst Francais Du Petrole | Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral |
| JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
-
2004
- 2004-05-24 JO JO200466A patent/JO2785B1/en active
- 2004-05-24 PA PA20048603801A patent/PA8603801A1/es unknown
- 2004-05-25 EP EP10192741A patent/EP2305687A1/en not_active Withdrawn
- 2004-05-25 JP JP2006529915A patent/JP4887151B2/ja not_active Expired - Lifetime
- 2004-05-25 PT PT04739341T patent/PT1633365E/pt unknown
- 2004-05-25 EA EA200501866A patent/EA009064B1/ru unknown
- 2004-05-25 MY MYPI20042004A patent/MY148633A/en unknown
- 2004-05-25 HR HRP20120351TT patent/HRP20120351T1/hr unknown
- 2004-05-25 UA UAA200510181A patent/UA84010C2/ru unknown
- 2004-05-25 CL CL200401267A patent/CL2004001267A1/es unknown
- 2004-05-25 SI SI200431864T patent/SI1633365T1/sl unknown
- 2004-05-25 KR KR1020057022189A patent/KR101143878B1/ko not_active Expired - Lifetime
- 2004-05-25 CN CN201210144221.7A patent/CN102718775B/zh not_active Expired - Lifetime
- 2004-05-25 DK DK04739341.8T patent/DK1633365T3/da active
- 2004-05-25 US US10/558,007 patent/US7648975B2/en not_active Expired - Lifetime
- 2004-05-25 MX MXPA05012762A patent/MXPA05012762A/es active IP Right Grant
- 2004-05-25 PL PL04739341T patent/PL1633365T3/pl unknown
- 2004-05-25 NZ NZ544154A patent/NZ544154A/en not_active IP Right Cessation
- 2004-05-25 CA CA2525214A patent/CA2525214C/en not_active Expired - Lifetime
- 2004-05-25 WO PCT/EP2004/005621 patent/WO2004105765A1/en not_active Ceased
- 2004-05-25 BR BRPI0410714A patent/BRPI0410714B8/pt not_active IP Right Cessation
- 2004-05-25 AT AT04739341T patent/ATE544454T1/de active
- 2004-05-25 EP EP04739341A patent/EP1633365B1/en not_active Expired - Lifetime
- 2004-05-25 ES ES04739341T patent/ES2381976T3/es not_active Expired - Lifetime
- 2004-05-25 AU AU2004243487A patent/AU2004243487B2/en not_active Expired
- 2004-05-26 TW TW093114851A patent/TWI379835B/zh not_active IP Right Cessation
- 2004-05-26 TW TW101115204A patent/TWI468372B/zh not_active IP Right Cessation
- 2004-05-26 TW TW101115205A patent/TWI468397B/zh not_active IP Right Cessation
- 2004-05-26 AR ARP040101806A patent/AR045687A1/es active IP Right Grant
-
2005
- 2005-10-14 IS IS8077A patent/IS3030B/is unknown
- 2005-11-24 CO CO05119403A patent/CO5640038A2/es active IP Right Grant
- 2005-11-24 IL IL172154A patent/IL172154A0/en active IP Right Grant
- 2005-12-27 NO NO20056196A patent/NO334209B1/no unknown
-
2009
- 2009-11-24 US US12/624,637 patent/US8394786B2/en not_active Expired - Lifetime
-
2012
- 2012-05-08 CY CY20121100428T patent/CY1113002T1/el unknown
-
2013
- 2013-01-18 US US13/744,878 patent/US9273013B2/en not_active Expired - Lifetime
- 2013-08-15 AR ARP130102897A patent/AR092137A2/es unknown
-
2014
- 2014-06-10 IL IL233046A patent/IL233046A0/en active IP Right Grant
- 2014-06-10 IL IL233045A patent/IL233045B/en active IP Right Grant
-
2016
- 2016-01-21 US US15/003,124 patent/US20160207938A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO339891B1 (no) * | 2004-12-08 | 2017-02-13 | Janssen Pharmaceutica Nv | MTKI kinazolinderivater |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20056196L (no) | Makrocykliske kinazolinderivater som antiproliferative midler | |
| NO20063323L (no) | Pyrido- og pyrimidopyrimidinderivater | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| AP1753A (en) | Thiophene derivatives as antiviral agents for flavvivirus infection | |
| AR030762A1 (es) | Piridinilamidas e imidas para usar como fungicidas | |
| NO20051411L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav | |
| WO2007003525A3 (en) | Cyclic anilino-pyridinotriazines as gsk-3 inhibitors | |
| DK1389617T3 (da) | Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| NO20091394L (no) | Pyridin-4-yl-derivater som immunmodulerende midler | |
| NO20052493L (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger. | |
| TW200616541A (en) | Benzoyl-substituted serineamides | |
| MY134701A (en) | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
| WO2008140099A1 (ja) | テトラゾイルオキシム誘導体および植物病害防除剤 | |
| TNSN08522A1 (en) | Cinnamoyl-piperazine derivatives and their use as par - 1 antagonists | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof | |
| IL163625A0 (en) | Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same | |
| UA84724C2 (ru) | Производные пиримидина, гербицидные смеси и композиции на их основе, способ контроля роста нежелательной растительности | |
| NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav | |
| NO20062474L (no) | Antivirale midler bestaende av diazaindol-dikarbonyl-piperazinyl | |
| EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина | |
| IL173810A0 (en) | Imidazopyridine derivatives and pharmaceutical compositions containing the same |